To validate the clustering results of IgA+CD20+, IgG1+ and IgG2+ B cells in MS pathogenesis and response to alemtuzumab treatment, manual gating was performed to identify conventional B‐cell subsets (Figure 3a, Supplementary figure 1). Here, CD79A is linked to myeloid sarcoma.